Letrozole; Ribociclib Succinate Patent Expiration
Letrozole; Ribociclib Succinate is Used for the initial endocrine-based therapy in adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer. It was first introduced by Novartis Pharmaceuticals Corp
Letrozole; Ribociclib Succinate Patents
Given below is the list of patents protecting Letrozole; Ribociclib Succinate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Kisqali Femara Co-pack (copackaged) | US10799506 | Ribociclib tablet | Apr 14, 2036 | Novartis |
| Kisqali Femara Co-pack (copackaged) | US12064434 | Ribociclib tablet | Apr 14, 2036 | Novartis |
| Kisqali Femara Co-pack (copackaged) | US9193732 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | Nov 09, 2031 | Novartis |
| Kisqali Femara Co-pack (copackaged) | US9868739 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | Nov 09, 2031 | Novartis |
| Kisqali Femara Co-pack (copackaged) | US8415355 | Pyrrolopyrimidine compounds and their uses | Mar 13, 2031 | Novartis |
| Kisqali Femara Co-pack (copackaged) | US8685980 | Pyrrolopyrimidine compounds and their uses | May 25, 2030 | Novartis |
| Kisqali Femara Co-pack (copackaged) | US8962630 | Pyrrolopyrimidine compounds and their uses | Dec 09, 2029 | Novartis |
| Kisqali Femara Co-pack (copackaged) | US9416136 | Pyrrolopyrimidine compounds and their uses | Aug 20, 2029 | Novartis |
| Kisqali Femara Co-pack (copackaged) | US8324225 | Pyrrolopyrimidine compounds and their uses | Jun 17, 2028 | Novartis |
Letrozole; Ribociclib Succinate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List